Core Viewpoint - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments, particularly through its lead product candidate, atebimetinib, which targets various cancer indications [1][3]. Group 1: Company Overview - Immuneering Corporation is dedicated to keeping cancer patients alive and helping them thrive by developing a new category of cancer medicines known as Deep Cyclic Inhibitors [3]. - The lead product candidate, atebimetinib, is an oral, once-daily medication designed to improve durability and tolerability for patients with MAPK pathway-driven tumors, including pancreatic cancer [3]. - A Phase 3 trial for atebimetinib in first-line pancreatic cancer is expected to begin dosing in mid-2026 [3]. Group 2: Upcoming Events - Management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, discussing the company's pipeline, platform, and business strategy [1]. - The presentation is scheduled for February 26, 2026, at 10:00 am ET and will be available via live webcast and archived on the company's Investor Relations website [2].

Core Viewpoint - Immuneering Corporation is set to be added to the Nasdaq Biotechnology Index, effective prior to market open on December 22, 2025, highlighting its growing recognition in the biotechnology sector [1]. Company Overview - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments, specifically a new category of medicines known as Deep Cyclic Inhibitors [3]. - The lead product candidate, atebimetinib, is an oral medication designed to improve durability and tolerability for various cancer types, including pancreatic cancer, and is expected to enter a Phase 3 trial in mid-2026 [3]. Nasdaq Biotechnology Index (NBI) Details - The NBI tracks the performance of biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market, with specific eligibility requirements such as minimum market capitalization and average daily trading volume [2]. - The index is evaluated annually in December and employs a modified capitalization-weighted methodology for its calculations [2].

Core Insights - Immuneering Corporation is a clinical-stage oncology company focused on developing innovative cancer treatments to improve patient survival and quality of life [3] Company Presentation - Immuneering will present at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 4, from 11:10 to 11:30 a.m. ET [2] - The presentation will be available via live webcast and archived on the company's Investor Relations website [2] Product Development - Immuneering is developing a new category of cancer medicines called Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib, currently in a Phase 2a trial for advanced solid tumors, including pancreatic cancer [3] - Atebimetinib is designed to be an oral, once-daily medication that enhances durability and tolerability across various cancer indications, particularly those driven by the MAPK pathway [3]

Core Viewpoint - Immuneering Corporation has successfully closed a private placement, raising approximately $25 million from institutional and accredited investors, aimed at advancing its oncology drug development efforts [1][2]. Group 1: Private Placement Details - The private placement involved the sale of 6,329,113 unregistered shares of Class A common stock at a price of $3.95 per share, along with purchase warrants for an additional 2,848,096 shares at an exercise price of $5.50 per share [2]. - The pre-funded warrants were issued at a price of $3.949 per share, reflecting the common stock price minus a nominal exercise price [2]. - Investors received registration rights as part of the transaction, and the purchase warrants are exercisable for five years post-registration [2]. Group 2: Company Overview - Immuneering is a clinical-stage oncology company focused on developing Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib (IMM-1-104), currently in a Phase 2a trial for advanced solid tumors, including pancreatic cancer [5]. - The company aims to improve the durability and tolerability of cancer treatments and expand indications for MAPK pathway-driven tumors [5].